TMDX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
203.0M
+6.9%
189.9M
+9.2%
173.9M
+8.2%
160.8M
+11.8%
143.8M
Cost of Revenue
84.3M
+9.9%
76.8M
+5.5%
72.8M
+8.1%
67.3M
+13.7%
59.2M
Gross Profit
118.7M
+4.8%
113.2M
+11.9%
101.2M
+8.3%
93.4M
+10.5%
84.6M
Operating Expenses
90.5M
+1.2%
89.5M
+1.8%
87.9M
+21.8%
72.1M
+17.7%
61.3M
R&D
29.2M
-7.7%
31.6M
+27.1%
24.9M
+20.2%
20.7M
+35.7%
15.3M
SG&A
61.3M
+6.1%
57.8M
-8.2%
63.0M
+22.4%
51.4M
+11.8%
46.0M
Operating Income
28.1M
+18.6%
23.7M
+78.5%
13.3M
-37.5%
21.3M
-8.7%
23.3M
EBITDA
39.0M
+14.7%
34.0M
+35.0%
25.2M
-12.5%
28.7M
-4.7%
30.1M
Net Income
17.1M
+16.3%
14.7M
+100.7%
7.3M
-93.1%
105.4M
+333.3%
24.3M
EPS (Basic)
$0.49
+16.7%
$0.42
+100.0%
$0.21
-93.2%
$3.08
+333.8%
$0.71
EPS (Diluted)
$0.46
+12.2%
$0.41
+105.0%
$0.20
-92.2%
$2.57
+289.4%
$0.66
Shares (Diluted)
40.8M
+0.3%
40.7M
+12.5%
36.2M
-11.6%
40.9M
+0.5%
40.7M
TransMedics (TMDX) — Financials